SCHEMBL19429857

SCHEMBL19429857

CNCCN(C)Cc1cccc(-c2cc(C(=O)N3CCC3)c3c(n2)N(C(C)C)NC3)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 5/20 0.39
▸ POLB P06746 1/20 0.35
▸ MOK Q9UQ07 2/20 0.34
▸ WNK1 Q9H4A3 1/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ CARM1 Q86X55 1/20 0.33
▸ PRMT1 Q99873 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ PLAUR Q03405 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19430238 0.98 PRMT6 (0.39) PRMT6POLBMOKWNK1TDP1
SCHEMBL19429973 0.93 PRMT6 (0.48) PRMT6POLBMOKKDM4EALDH1A1
SCHEMBL19429853 0.91 AOC3 (0.41) POLBWNK1KDM4EALDH1A1SMN1; SMN2
SCHEMBL19429860 0.90 SMN1; SMN2 (0.44) PRMT6KDM4EALDH1A1SMN1; SMN2MAPT
SCHEMBL19430109 0.90 PRMT6 (0.37) PRMT6MOKWNK1CARM1PRMT1
SCHEMBL19429963 0.90 PRMT6 (0.37) PRMT6MOKWNK1
SCHEMBL19430299 0.89 PRMT6 (0.36) PRMT6MOKWNK1KDM4EPRMT1
SCHEMBL19430232 0.88 AOC3 (0.40) POLBWNK1TDP1KMT2A
SCHEMBL19430139 0.88 PRMT6 (0.41) PRMT6MOKCARM1PRMT1
SCHEMBL19430397 0.84 AOC3 (0.48) PRMT6POLBKDM4EALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170280720-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT6 4/4885POLB 2003/4885MOK 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback